Sudocrem boss: new skin drug will net €1.5bn
Drug will be used to treat epidermolysis bullosa
A new publicly quoted pharmaceutical company backed by Sudocrem founder Dr Ray Stafford is predicting revenues of up to $1.5 billion from one of its drugs, which is used to treat rare genetic skin disorders.
The drug, which is currently going through ...